Encouraging early results in Alzheimer's for Prothena

26 July 2021

Ireland-based company Prothena Corporation (Nasdaq: PRTA) has presented new data at the Alzheimer’s Association International Conference 2021 (AAIC) from two of its programs.

The presentations highlight pre-clinical data for PRX012, Prothena’s next-generation anti-amyloid beta (Aβ) antibody being developed for subcutaneous administration for patients with Alzheimer’s disease (AD), as well as data on the company’s dual Aβ-tau vaccine program being developed for the prevention and treatment of AD.

These two programs and Prothena’s anti-tau antibody partnered with Bristol Myers Squibb (NYSE: BMY), PRX005, are part of the company’s AD portfolio.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK